Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Deloitte
UBS
Boehringer Ingelheim
Medtronic
Healthtrust
Covington
QuintilesIMS
Colorcon
Johnson and Johnson

Generated: August 18, 2017

DrugPatentWatch Database Preview

Naloxone hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for naloxone hydrochloride and what is the scope of naloxone hydrochloride freedom to operate?

Naloxone hydrochloride
is the generic ingredient in seven branded drugs marketed by Abraxis Pharm, Marsam Pharms Llc, Bristol Myers Squibb, Adapt, Mylan Institutional, Intl Medication, Watson Labs, Hospira, Kaleo Inc, Akorn, Smith And Nephew, Eurohlth Intl Sarl, Solopak, Astrazeneca, Igi Labs Inc, Wyeth Ayerst, West-ward Pharms Int, Purdue Pharma Lp, Sun Pharm Inds Ltd, Sanofi Aventis Us, and Gavis Pharms, and is included in sixty-three NDAs. There are forty-eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Naloxone hydrochloride has one hundred and forty-two patent family members in seventeen countries.

There are twelve drug master file entries for naloxone hydrochloride. Fifteen suppliers are listed for this compound.

Summary for Generic Name: naloxone hydrochloride

Tradenames:7
Patents:48
Applicants:21
NDAs:63
Drug Master File Entries: see list12
Suppliers / Packagers: see list15
Bulk Api Vendors: see list49
Clinical Trials: see list2,464
Patent Applications: see list6,617
Therapeutic Class:Antidotes, Deterrents, and Toxicologic Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:naloxone hydrochloride at DailyMed

Pharmacology for Ingredient: naloxone hydrochloride

Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kaleo Inc
EVZIO
naloxone hydrochloride
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS205787-001Apr 3, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Kaleo Inc
EVZIO
naloxone hydrochloride
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS209862-001Oct 19, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Eurohlth Intl Sarl
NALOXONE HYDROCHLORIDE
naloxone hydrochloride
INJECTABLE;INJECTION071274-001May 24, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
Purdue Pharma Lp
TARGINIQ
naloxone hydrochloride; oxycodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL205777-003Jul 23, 2014DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Wyeth Ayerst
NALOXONE
naloxone hydrochloride
INJECTABLE;INJECTION070191-001Sep 24, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: naloxone hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,172,082Devices, systems and methods for medicament delivery► Subscribe
9,327,077Medical injector with compliance tracking and monitoring► Subscribe
9,022,980Medical injector simulation device► Subscribe
7,416,540Devices systems and methods for medicament delivery► Subscribe
9,724,471Devices, systems, and methods for medicament delivery► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: naloxone hydrochloride

Country Document Number Estimated Expiration
Canada2905774► Subscribe
Spain2396745► Subscribe
Hong Kong1126992► Subscribe
World Intellectual Property Organization (WIPO)2010056712► Subscribe
New Zealand555256► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: NALOXONE HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
292Luxembourg► SubscribePRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
UBS
Teva
Fish and Richardson
Argus Health
Queensland Health
Chubb
US Department of Justice
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot